The purpose of this study is to evaluate the safety and efficacy of long-term treatment with TAK-875 in diabetic patients.
Inclusion Criteria:
Exclusion Criteria:
Funabashi-shi, Chiba, Japan
Kisarazu-shi, Chiba, Japan
Matsudo-shi, Chiba, Japan
Nihama-shi, Ehime, Japan
Saijo-shi, Ehime, Japan
Kitakyushu-shi, Fukuoka, Japan
Onga-gun, Fukuoka, Japan
Annaka-shi, Gunma, Japan
Takasaki-shi, Gunma, Japan
Aki-gun, Hiroshima, Japan
Chitose-shi, Hokkaido, Japan
Amagasaki-shi, Hyōgo, Japan
Nishinomiya-shi, Hyōgo, Japan
Tsuchiura-shi, Ibaragi, Japan
Ushiku-shi, Ibaragi, Japan
Sakade-shi, Kagawa-ken, Japan
Izumi-shi, Kagoshima-ken, Japan
Kamakura-shi, Kanagawa, Japan
Yamato-shi, Kanagawa, Japan
Suzaki-shi, Kochi, Japan
Minamata-shi, Kumamoto, Japan
Uji-shi, Kyoto, Japan
Matsumoto-shi, Nagano, Japan
Omura-shi, Nagasaki, Japan
Kashiwara-shi, Osaka, Japan
Sakai-shi, Osaka, Japan
Suita-shi, Osaka, Japan
Toyonaka-shi, Osaka, Japan
Fujimi-shi, Saitama, Japan
Saitama-shi, Saitama, Japan
Sayama-shi, Saitama, Japan
Tokorozawa-shi, Saitama, Japan
Fujinomiya-shi, Shizuoka, Japan
Shimotsuga-gun, Tochigi, Japan
Shimotsuke-shi, Tochigi, Japan
Komatsu-shi, Tokushima, Japan
Bunkyo-ku, Tokyo, Japan
Chiyoda-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan
Hino-shi, Tokyo, Japan
Itabashi-ku, Tokyo, Japan
Mitaka-shi, Tokyo, Japan
Nerima-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Sibuya-ku, Tokyo, Japan
Toyoshima-ku, Tokyo, Japan
Sanyoonoda-shi, Yamaguchi, Japan
Shimonoseki-shi, Yamaguchi, Japan
Ube-shi, Yamaguchi, Japan